Eli Lilly’s relaxin study stopped early over low probability of benefit

According to a report from Nature Medicine over the weekend, a study of Eli Lilly’s (LLY) relaxin, a peptide hormone that may decrease circulatory congestion and improve kidney function, was stopped early by the sponsor after the first interim analysis because a low probability of observing benefit with continued enrollment was interpreted. Although there was not evidence of increased HF events in the volenrelaxin group, multiple signals for worsening congestion were perceived, which motivated the decision to terminate the study prematurely. A total of 170 patients outt of 332 completed the full 26-week protocol.